2 citations
,
December 2019 in “Neurobiology of Stress” Changing allopregnanolone levels in baby rats affects their adult behavior and alcohol use.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
1 citations
,
January 2013 in “Digital Scholarship - UNLV (University of Nevada Reno)” Targeting neurosteroids may help prevent drug relapse.
1 citations
,
January 1980 in “Side effects of drugs annual” Taking too much vitamin A can cause health problems like bone pain and hair loss.
September 2014 in “Springer eBooks” The document concludes that breast pain should be managed with personalized treatment, starting with non-drug methods and progressing to medication if necessary, while considering side effects and patient needs.
September 2023 in “Journal of movement disorders” Dopaminergic therapy in Parkinson's disease patients is linked to increased hair loss.
Polydopamine is promising for personalized medicine and biomedical technology due to its strong adhesion and biocompatibility.
2 citations
,
March 2023 in “Experimental neurology” Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.
October 2022 in “Amplla Editora eBooks” Deep Brain Stimulation helps manage Parkinson's symptoms when medication isn't enough.
The data suggests that dosing differences can help manage spasticity in patients with upper motor neuron dysfunction.
April 2025 in “International Journal of Clinical & Medical Case Studies” Dextroamphetamine may help treat alopecia areata.
July 2023 in “Developmental medicine and child neurology/Developmental medicine & child neurology” DFMO treatment improves hair growth, muscle tone, and development in Bachmann-Bupp syndrome patients.
November 2008 in “British Journal of Hospital Medicine” Non-drug methods effectively managed agitation in a patient with a heart device, leading to improved mental function.
July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
October 2009 in “Nature Reviews Urology” Dexmedetomidine-loaded microneedles effectively reduce pain without sedation.
May 2026 in “International Journal of Drug Delivery Technology” Adrenaline infiltration improves hair transplant efficiency and safety.
July 2004 in “Journal of Clinical Oncology” Isolated hyperthermic chemotherapy perfusion for limb melanoma is safe and effective with manageable side effects.
1 citations
,
April 2025 in “American Journal of Medical Genetics Part C Seminars in Medical Genetics” Eflornithine improved symptoms in Bachmann–Bupp Syndrome patients.
June 1995 in “International Journal of Gynecology & Obstetrics” Cabergoline is more effective and has fewer side effects than bromocriptine for treating women with hyperprolactinemic amenorrhea.
February 2006 in “Inpharma Weekly” 15 citations
,
June 2019 in “Biochemical Journal” A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.
July 2004 in “Journal of Clinical Oncology” Isolated limb perfusion is a safe and effective treatment for limb melanoma.
December 2024 in “African Journal of Biomedical Research” Combining dexmedetomidine and ketamine provides better sedation and pain relief than dexmedetomidine alone.
12 citations
,
October 2012 in “International Braz J Urol” Finasteride effectively and safely treats recurrent priapism in children and adolescents with sickle cell disease.
February 2026 in “Skin Appendage Disorders” Scalp microinfusion with dutasteride is a safe and promising treatment for male hair loss.
17 citations
,
August 1967 in “JAMA” The rapid corticotropin test is a quick and simple way to diagnose adrenal insufficiency.
February 2019 in “Neoreviews” The infant with a urea cycle disorder improved with treatment and a liver transplant.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.